Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANDMAN: BAY2253651 in obstructive sleep apnea
NCT03603678Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BAY2253651 in obstructive sleep apnea (OSA) (3 arms), sponsored by Bayer. Primary endpoint: Rate of responders, defined by reduction of apnoea-hypopnoea-index (AHI) from baseline by >= 50% at 2 days. Started Aug 2018; status: completed.
02
Drugs
BAY2253651
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03603678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603678.